Stay updated on KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Sign up to get notified when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.

Latest updates to the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page
- Check6 days agoChange DetectedRevision: v3.3.2 was added, replacing the previous v3.3.1.SummaryDifference0.1%

- Check13 days agoChange DetectedThe Publications section wording was clarified to indicate results of the study, and the revision note updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check20 days agoChange DetectedNotice about government funding lapse and operating status updates has been removed from the page; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check34 days agoChange DetectedThe updates are minor adjustments that do not modify core study details such as eligibility, endpoints, or enrollment. The study’s primary purpose remains unchanged.SummaryDifference0.5%

- Check63 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference2%

- Check70 days agoChange DetectedUpdate includes a version upgrade to v3.1.0 and removal of v3.0.2, with several added and removed contact details and identifiers.SummaryDifference0.1%

Stay in the know with updates to KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer
Enter your email address, and we'll notify you when there's something new on the KEYDOX Trial: Doxorubicin & Pembrolizumab in Breast Cancer page.